Hepion Pharma Appoints Dr. Todd Hobbs to Board of Directors
Ticker: CTRVP · Form: 8-K · Filed: Feb 7, 2024 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 8-K |
| Filed Date | Feb 7, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: board-change, corporate-governance, director-appointment
TL;DR
**Hepion Pharma just added a new director, Dr. Todd Hobbs, to its board and key committees.**
AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) announced on February 7, 2024, that Dr. Todd Hobbs was appointed as a Class I Director to its Board of Directors. Dr. Hobbs will also serve on the Audit Committee and the Nominating and Corporate Governance Committee. This matters to investors because adding a new director, especially one with a background like Dr. Hobbs, can bring fresh perspectives and expertise to the company's strategic decisions, potentially influencing future drug development and financial performance.
Why It Matters
The addition of Dr. Todd Hobbs to the board and key committees could enhance Hepion's governance and strategic direction, potentially impacting its drug development pipeline and investor confidence.
Risk Assessment
Risk Level: low — This filing reports a routine board appointment, which generally carries a low risk for investors.
Analyst Insight
Investors should monitor future announcements from Hepion Pharmaceuticals for any strategic shifts or new initiatives that may arise from the board's enhanced composition, particularly regarding drug development or corporate governance.
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — the registrant
- Dr. Todd Hobbs (person) — appointed as a Class I Director
- February 7, 2024 (date) — date of earliest event reported
- Nasdaq Capital Market (company) — exchange where HEPA Common Stock is registered
FAQ
What is the primary event reported in this 8-K filing by Hepion Pharmaceuticals, Inc.?
The primary event reported is the appointment of Dr. Todd Hobbs as a Class I Director to the Board of Directors of Hepion Pharmaceuticals, Inc. on February 7, 2024.
What specific committees will Dr. Todd Hobbs serve on at Hepion Pharmaceuticals?
Dr. Todd Hobbs will serve on the Audit Committee and the Nominating and Corporate Governance Committee of Hepion Pharmaceuticals, Inc.
What is the trading symbol for Hepion Pharmaceuticals, Inc. common stock?
The trading symbol for Hepion Pharmaceuticals, Inc. common stock is HEPA.
On which exchange is Hepion Pharmaceuticals, Inc. common stock registered?
Hepion Pharmaceuticals, Inc. common stock is registered on the Nasdaq Capital Market.
What is the business address of Hepion Pharmaceuticals, Inc.?
The business address of Hepion Pharmaceuticals, Inc. is 399 Thornall Street, First Floor, Edison, NJ 08837.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 13.7 · Accepted 2024-02-07 16:15:30
Filing Documents
- tm245471d1_8k.htm (8-K) — 22KB
- 0001104659-24-011616.txt ( ) — 192KB
- hepa-20240207.xsd (EX-101.SCH) — 3KB
- hepa-20240207_lab.xml (EX-101.LAB) — 33KB
- hepa-20240207_pre.xml (EX-101.PRE) — 22KB
- tm245471d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 7, 2024, Anand Reddi resigned from the Board of Directors of Hepion Pharmaceuticals, Inc. (the "Company"). Mr. Reddi was Chairman of the Company's Compensation Committee and a member of the Corporate Governance/Nominations Committee. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 7, 2024 HEPION PHARMACEUTICALS, INC. By: /s/ John Cavan John Cavan Interim Chief Executive Officer and Chief Financial Officer -3-